The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 14, 2021

Filed:

Jan. 07, 2020
Applicant:

Wyeth Holdings Llc, New York, NY (US);

Inventors:

Gary W. Zlotnick, San Antonio, TX (US);

Leah D. Fletcher, Geneseo, NY (US);

John E. Farley, Chapel Hill, NC (US);

Liesel A. Bernfield, Rochester, NY (US);

Robert J. Zagursky, Victor, NY (US);

Benjamin J. Metcalf, Rochester, NY (US);

Assignee:

Wyeth Holdings LLC, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/095 (2006.01); C07K 14/22 (2006.01); A61K 47/64 (2017.01); C07K 16/12 (2006.01); G01N 33/569 (2006.01); A61K 47/54 (2017.01); C12N 9/28 (2006.01); C12N 9/40 (2006.01); C12N 9/38 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/095 (2013.01); A61K 39/39 (2013.01); A61K 47/543 (2017.08); A61K 47/646 (2017.08); C07K 14/22 (2013.01); C07K 16/1217 (2013.01); C12N 9/2417 (2013.01); C12N 9/2465 (2013.01); C12N 9/2471 (2013.01); G01N 33/56911 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/58 (2013.01); A61K 2039/6087 (2013.01); G01N 2333/22 (2013.01); Y10S 530/825 (2013.01);
Abstract

The present invention relates toORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection byserogroup B.


Find Patent Forward Citations

Loading…